HOUSTON INNOVATORS PODCAST EPISODE 68

Houston health tech founder shares the monumental impact data can have on health care

Jim Havelka, founder and CEO of InformAI, joins the Houston Innovators Podcast to discuss the difference his technology can make on the health care industry. Photo courtesy of InformAI

Hospitals are processing massive amounts of data on a daily basis — but few are optimizing this information in life-saving capacities. A Houston company is seeking to change that.

InformAI has created several tech products to allow hospitals to tap into their data for game-changing health care.

"The convergence of technology, data, and deep learning has really opened up an avenue to look at large volumes of information and look at patterns that can be helpful in patient diagnosis and treatment planning," says CEO Jim Havelka on this week's episode of the Houston Innovators Podcast.

The InformAI team has developed two platforms that each of the company's tech products works within. One focuses on medical images and looks for subtle patterns of a medical condition, while the other can datamine patient information to identify patient risk predictors.

Currently, InformAI's sinusitis-focused product is undergoing Food and Drug Administration approval. About a quarter of the population has sinus-related issues, and the technology can help treatment and diagnosis, Havelka says.

"The data that we train our algorithms on are equivalent of 30 careers of a typical ear, nose, and throat surgeon. We see 30 times more patients in our training set than an ENT physician would see in a lifetime," Havelka says. "Being able to bring into play the patterns and unique subtleties that this data can bring into the decision making only makes the ENT more productive and more efficient, as well as creates better outcomes for patients."

InformAI has received venture capital support as well as a National Science Foundation award to advance its work. The company hopes to introduce a new round of funding later this year.

Havelka doesn't mince words when it comes to the importance of InformAI being located in Houston. The company's team works out of JLABS @ TMC as well as TMC Innovation Institute.

"Those relationships have been very helpful in getting data to build these particular products," Havelka says. "Just the Texas Medical Center alone has roughly 10 million patient encounters every year. The ability to get access to data and, equally important, the medical experts has been a tremendous benefit to InformAI."

Havelka discusses more about the revolutionary technology InformAI is working on — as well as advice he has for other health tech founders — on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News